NCT04805983View on ClinicalTrials.gov

Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

April 24, 2022

Study Completion Date

April 24, 2022

Conditions
Alzheimer Disease
Interventions
DRUG

BMS-984923

Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.

Trial Locations (1)

06520

Yale University, New Haven

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Yale University

OTHER

NCT04805983 - Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923 | Biotech Hunter | Biotech Hunter